openPR Logo
Press release

Pediatric Brain Tumors Pipeline 2024: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment By DelveInsight | Laminar Pharma, Cellectar Biosciences, Oncoceutics, Novartis, Ziopharm, Moleculin Biotech

01-29-2025 07:27 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Pediatric Brain Tumors Pipeline 2024: Latest FDA Approvals,

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Pediatric Brain Tumors pipeline constitutes 5+ key companies continuously working towards developing 5+ Pediatric Brain Tumors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Pediatric Brain Tumors Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pediatric Brain Tumors Market.

The Pediatric Brain Tumors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Pediatric Brain Tumors Pipeline Report: https://www.delveinsight.com/sample-request/pediatric-brain-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Pediatric Brain Tumors treatment therapies with a considerable amount of success over the years.
• Pediatric Brain Tumors companies working in the treatment market are Moleculin Biotech, Cellectar Biosciences, Oncoceutics, Chimerix, Kazia TherapeuticsLaminar Pharmaceuticals, Abbott, AbbVie Inc., Akorn, Inc., Agios, Inc., Baxter, Bayer AG, Epizyme, Inc., Novar, tis AG, Mylan N.V., and others, are developing therapies for the Pediatric Brain Tumors treatment
• Emerging Pediatric Brain Tumors therapies in the different phases of clinical trials are- LP561A1, GDC-008, ONC201, CLR-131, WP1066, and others are expected to have a significant impact on the Pediatric Brain Tumors market in the coming years.
• In January 2025, BrainChild Bio, Inc., a clinical-stage biotechnology company focused on developing CAR T-cell therapies for treating central nervous system (CNS) tumors, announced its clinical development plan to advance BCB-276. This lead autologous CAR T-cell therapy targets the immune checkpoint B7-H3 and is being developed for diffuse intrinsic pontine glioma (DIPG), an incurable pediatric brain tumor.
• In December 2024, Matica Biotechnology (Matica Bio), a prominent contract development and manufacturing organization (CDMO) specializing in viral vector development and production, announced a strategic partnership with Treovir. The collaboration aims to advance innovative therapies for pediatric patients with brain and other neurological cancers, with Matica Bio providing GMP manufacturing for clinical supplies.
• In May 2024, The Children's Cancer Institute in Australia unveiled a new clinical trial targeting the treatment of the deadly childhood brain cancer known as Diffuse Intrinsic Pontine Glioma (DIPG). Named Levi's Catch, this trial is the first of its kind to be conducted outside the US and will be carried out by medical professionals at Sydney Children's Hospital in Randwick (SCH).

Pediatric Brain Tumors Overview
Pediatric brain tumors are abnormal growths of cells that occur in the brain or the tissue near it in children. These tumors can be benign (non-cancerous) or malignant (cancerous) and can vary significantly in terms of their location, growth rate, and the symptoms they cause.

Get a Free Sample PDF Report to know more about Pediatric Brain Tumors Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/pediatric-brain-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Pediatric Brain Tumors Drugs Under Different Phases of Clinical Development Include:
• LP561A1: Laminar Pharmaceuticals
• GDC-008: Kazia Therapeutics
• ONC201: Oncoceutics/ Chimerix
• CLR-131: Cellectar Biosciences
• WP1066: Moleculin Biotech

Pediatric Brain Tumors Route of Administration
Pediatric Brain Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Pediatric Brain Tumors Molecule Type
Pediatric Brain Tumors Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Pediatric Brain Tumors Pipeline Therapeutics Assessment
• Pediatric Brain Tumors Assessment by Product Type
• Pediatric Brain Tumors By Stage and Product Type
• Pediatric Brain Tumors Assessment by Route of Administration
• Pediatric Brain Tumors By Stage and Route of Administration
• Pediatric Brain Tumors Assessment by Molecule Type
• Pediatric Brain Tumors by Stage and Molecule Type

DelveInsight's Pediatric Brain Tumors Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Pediatric Brain Tumors product details are provided in the report. Download the Pediatric Brain Tumors pipeline report to learn more about the emerging Pediatric Brain Tumors therapies
https://www.delveinsight.com/sample-request/pediatric-brain-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Pediatric Brain Tumors Therapeutics Market include:
Key companies developing therapies for Pediatric Brain Tumors are - Laminar Pharmaceuticals, Cellectar Biosciences, Oncoceutics, Novartis, Ziopharm, Moleculin Biotech, Candel Therapeutics, Celgene, Kazia Therapeutics, and others.

Pediatric Brain Tumors Pipeline Analysis:
The Pediatric Brain Tumors pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Pediatric Brain Tumors with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pediatric Brain Tumors Treatment.
• Pediatric Brain Tumors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pediatric Brain Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pediatric Brain Tumors market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Pediatric Brain Tumors drugs and therapies
https://www.delveinsight.com/sample-request/pediatric-brain-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pediatric Brain Tumors Pipeline Market Strengths
• Children with brain tumors generally have a better prognosis than adults with a similar condition
• Increased public awareness, improved access to health services, and awareness with disease understanding are identified on screening and diagnosis, thereby acting as a market driver

Pediatric Brain Tumors Pipeline Market Opportunities
• Currently, the pipeline of pediatric brain tumors has drugs in mid- and early phase of development. This provides a huge opportunity for the advent of innovative and effective novel therapies and targeted treatments

Scope of Pediatric Brain Tumors Pipeline Drug Insight
• Coverage: Global
• Key Pediatric Brain Tumors Companies: Moleculin Biotech, Cellectar Biosciences, Oncoceutics, Chimerix, Kazia TherapeuticsLaminar Pharmaceuticals, Abbott, AbbVie Inc., Akorn, Inc., Agios, Inc., Baxter, Bayer AG, Epizyme, Inc., Novar, tis AG, Mylan N.V., and others
• Key Pediatric Brain Tumors Therapies: LP561A1, GDC-008, ONC201, CLR-131, WP1066, and others
• Pediatric Brain Tumors Therapeutic Assessment: Pediatric Brain Tumors current marketed and Pediatric Brain Tumors emerging therapies
• Pediatric Brain Tumors Market Dynamics: Pediatric Brain Tumors market drivers and Pediatric Brain Tumors market barriers

Request for Sample PDF Report for Pediatric Brain Tumors Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/pediatric-brain-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Pediatric Brain Tumors Report Introduction
2. Pediatric Brain Tumors Executive Summary
3. Pediatric Brain Tumors Overview
4. Pediatric Brain Tumors- Analytical Perspective In-depth Commercial Assessment
5. Pediatric Brain Tumors Pipeline Therapeutics
6. Pediatric Brain Tumors Late Stage Products (Phase II/III)
7. Pediatric Brain Tumors Mid Stage Products (Phase II)
8. Pediatric Brain Tumors Early Stage Products (Phase I)
9. Pediatric Brain Tumors Preclinical Stage Products
10. Pediatric Brain Tumors Therapeutics Assessment
11. Pediatric Brain Tumors Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Pediatric Brain Tumors Key Companies
14. Pediatric Brain Tumors Key Products
15. Pediatric Brain Tumors Unmet Needs
16 . Pediatric Brain Tumors Market Drivers and Barriers
17. Pediatric Brain Tumors Future Perspectives and Conclusion
18. Pediatric Brain Tumors Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Pediatric Brain Tumors Market https://www.delveinsight.com/report-store/pediatric-brain-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Pediatric Brain Tumors Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Pediatric Brain Tumors Epidemiology https://www.delveinsight.com/report-store/pediatric-brain-tumors-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Pediatric Brain Tumors Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Sglt2 Inhibitors Market: https://www.delveinsight.com/report-store/sglt2-inhibitors-market
• Electroencephelographs Pipeline Insight: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight
• Fabry Disease Market: https://www.delveinsight.com/report-store/fabry-disease-market
• Dental Implants And Prosthesis Market: https://www.delveinsight.com/report-store/dental-implants-and-prosthesis-market
• Peritoneal Dialysis Equipment Market: https://www.delveinsight.com/report-store/peritoneal-dialysis-equipment-market Drug-eluting Stents Market Market: https://www.delveinsight.com/report-store/drug-eluting-stents-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pediatric Brain Tumors Pipeline 2024: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment By DelveInsight | Laminar Pharma, Cellectar Biosciences, Oncoceutics, Novartis, Ziopharm, Moleculin Biotech here

News-ID: 3840388 • Views:

More Releases from DelveInsight Business Research

Global Advanced Melanoma Pipeline Accelerates With 60+ Emerging Therapies, Reveals DelveInsight's 2025 Analysis
Global Advanced Melanoma Pipeline Accelerates With 60+ Emerging Therapies, Revea …
DelveInsight's "Advanced Melanoma Pipeline Insight 2025" report delivers an in-depth analysis of more than 55 companies and over 60 investigational therapies currently advancing through the Advanced Melanoma research landscape. It offers detailed profiles of both clinical- and preclinical-stage candidates and provides a thorough evaluation of therapies based on product type, development stage, route of administration, and molecule class. The report also outlines inactive or discontinued programs within this domain. Explore the
Global Spasticity Treatment Landscape Set for Transformation: DelveInsight Unveils Insights into 12+ Pipeline Therapies
Global Spasticity Treatment Landscape Set for Transformation: DelveInsight Unvei …
DelveInsight's "Spasticity Pipeline Insight, 2025" report offers an in-depth evaluation of 10+ companies and more than 12 investigational therapies currently advancing through the Spasticity treatment pipeline. The report includes detailed profiles of clinical- and preclinical-stage candidates, along with a thorough assessment of therapies by product type, development phase, route of administration, and molecular class. It also highlights discontinued and inactive programs in the field. Stay informed with the latest developments! Access
Lewy Body Dementia Treatment Market 2034 - Market Size, Competitive Landscape, Clinical Trials, Market Dynamics, Epidemiology, Companies | DelveInsight
Lewy Body Dementia Treatment Market 2034 - Market Size, Competitive Landscape, C …
The Lewy Body Dementia (LBD) market across the seven major markets (7MM) was valued at approximately USD 670 million in 2022, with strong growth anticipated through 2034. In 2022, an estimated 11 million dementia cases were recorded across the 7MM, of which ~0.6 million were attributed to Lewy Body Dementia. Rising disease prevalence-driven by aging demographics, enhanced diagnostic capabilities, and increasing awareness-is expected to stimulate market expansion. Companies including EIP
Bronchitis Treatment Market 2034: Market Size, Competitive Landscape, Companies, Clinical Trials, FDA Aprrovasls and Future Outlook by DelveInsight
Bronchitis Treatment Market 2034: Market Size, Competitive Landscape, Companies, …
The bronchitis therapeutics market is projected to grow steadily from 2025-2034, driven by rising disease prevalence, technological progress, and the emergence of new treatment options. Current management focuses on symptom relief through bronchodilators, corticosteroids, and antibiotics for acute cases, while chronic bronchitis requires long-term inhaled therapies, pulmonary rehabilitation, and lifestyle changes. A key advancement is the FDA-approved OHTUVAYRE (ensifentrine), which offers dual bronchodilator and anti-inflammatory benefits. Despite progress, there is

All 5 Releases


More Releases for Pediatric

Chronic Pediatric Conditions Fuels Growth In The Pediatric Radiology Market: An …
The Pediatric Radiology Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Projected Growth of the Pediatric Radiology Market? The pediatric radiology market, valued at $5.94 billion in 2024, is projected to increase to $6.29 billion in 2025, reflecting a CAGR of 5.9%. Growth
Pediatric Perfusion Market Experiences Growth with Increasing Pediatric Surgerie …
Market Overview Pediatric Perfusion Market size was valued at US$ 575.3 Mn in 2025 and is expected to reach US$ 842.5 Mn by 2032 growing at a compound annual growth rate (CAGR) of 5.6% from 2025 to 2032. Coherent Market Insights has released a comprehensive new report offering an in-depth analysis of the Pediatric Perfusion Market from 2025 to 2032. This study provides reliable global and regional projections, helping stakeholders navigate the
Adorable Smiles Pediatric Dentistry: Pediatric Dentist Corinth, TX
Adorable Smiles Pediatric Dentistry [https://adorablesmilestx.com/] is proud to provide exceptional dental care for children in Corinth, TX. Conveniently located at 3901 FM 2181 Suite 140, the practice is a trusted choice for families looking for pediatric dental services in Corinth TX. With a fun, child-friendly atmosphere, the team ensures that every visit is enjoyable and stress-free for kids. "Our goal is to create a positive dental experience for every child, building
Pediatric Interventional Cardiology Market: Advancements and Opportunities for P …
The report is generically segmented into six parts and every part aims on the overview of the Pediatric Interventional Cardiology Market industry, present condition of the market, feasibleness of the investment along with several strategies and policies. Apart from the definition and classification, the report also discusses the analysis of import and export and describes a comparison of the market that is focused on the trends and development. Along with
Pediatric Neuroblastoma Treatment Market - Redefining Possibilities: Advancement …
Newark, New Castle, USA: The "Pediatric Neuroblastoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Pediatric Neuroblastoma Treatment Market: https://www.growthplusreports.com/report/pediatric-neuroblastoma-treatment-market/7681 This latest report researches the industry structure,
Global Pediatric Vaccines Market | Global Pediatric Vaccines Industry | Global P …
The pediatric vaccines market involves of sales of pediatric vaccines and its linked services utilization to provide immunity to infants and children for specific syndromes. Pediatric vaccine is a preparation of killed the microorganisms, living tempered organisms, or living fully virulent organisms that are controlled to encourage the production of antibodies and deliver the immunity against one or numerous diseases among children. Pediatric vaccines are utilized in childhood immunization schedules